低HER2表达的卵巢癌肉瘤对曲妥珠单抗德鲁替康的反应：一例报告
Response of low HER2-expressing ovarian carcinosarcoma to trastuzumab deruxtecan, a case report.
作者信息
Rose Peter G
机构信息
Section of Gynecologic Oncology, Women's Health Institute, Cleveland Clinic, A-81, 9500 Euclid Ave., Cleveland, OH 44195, USA.
出版信息
Gynecol Oncol Rep. 2023 Nov 28;50:101311. doi: 10.1016/j.gore.2023.101311. eCollection 2023 Dec.
Abstract
•Treatment options are limited for recurrent ovarian carcinosarcoma (OCS).•A patient with HER2 1 + IHC and negative FISH amplification was treated with trastuzumab deruxtecan.•A durable partial response was achieved, suggesting a possible treatment option for OCS patients with HER2 expression.
摘要
•复发性卵巢癌肉瘤（OCS）的治疗选择有限。
•一名HER2免疫组化1+且荧光原位杂交（FISH）扩增阴性的患者接受了曲妥珠单抗德卢替康治疗。
•获得了持久的部分缓解，提示HER2表达的OCS患者可能有一个治疗选择。
Zotero 插件